ITC Begins Section 337 Investigation on Antirheumatic Drug
The International Trade Commission officially opened an investigation into alleged misappropriation of trade secrets relating to the manufacture of the antirheumatic drug Adalimumab. The investigation (ITC Inv. No. 337-TA-1296) is based on a complaint filed by AbbVie Dec. 17 (see…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
2112230048), alleging that Alvotech, Teva Pharmaceutical Industries and Ivers-Lee engaged in "a scheme to improperly recruit employees with knowledge of AbbVie's manufacturing process for Adalimumab," in an attempt to market a biosimilar called AVT02. AbbVie asked the ITC to issue a limited exclusion order and cease and desist orders banning importation and sale of covered goods by Alvotech, Teva and Ivers-Lee and their affiliates.